Opus Genetics
Yahoo Finance • 5 days ago
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bli... Full story
Yahoo Finance • 2 months ago
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.7% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
Opus Genetics rises as eye disease study to proceed without changes
[Arrow animation green screen, red color cartoon arrow pointing turn right on black background - 4K stock photo] kontekbrothers/iStock via Getty Images * Shares of Opus Genetics (IRD [https://seekingalpha.com/symbol/IRD]) traded higher... Full story
Yahoo Finance • 4 months ago
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mole... Full story
Yahoo Finance • 5 months ago
Opus Genetics GAAP EPS of -$0.25 misses by $0.12, revenue of $3.08M in-line
* Opus Genetics press release [https://seekingalpha.com/pr/20303379-opus-genetics-announces-financial-results-for-third-quarter-2025-and-provides-corporate] (IRD [https://seekingalpha.com/symbol/IRD]): Q3 GAAP EPS of -$0.25 misses by $0.... Full story
Yahoo Finance • 6 months ago
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited ret... Full story
Yahoo Finance • 6 months ago
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult particip... Full story
Yahoo Finance • 8 months ago
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company d... Full story
Yahoo Finance • 8 months ago
Opus Genetics earnings beat by $0.07, revenue fell short of estimates
Investing.com - Opus Genetics (NASDAQ: IRD) reported second quarter EPS of $-0.120, $0.07 better than the analyst estimate of $-0.190. Revenue for the quarter came in at $2.88M versus the consensus estimate of $4.04M. Opus Genetics’s stoc... Full story
Yahoo Finance • 8 months ago
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation fo... Full story
Yahoo Finance • 9 months ago
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mole... Full story
Yahoo Finance • 10 months ago
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the s... Full story
Yahoo Finance • 10 months ago
Opus Genetics CFO departs; Amy Rabourn named interim principal financial officer
Opus Genetics, Inc. (NASDAQ:IRD) announced Wednesday that Chief Financial Officer Nirav Jhaveri has departed the company following a termination without cause. According to a press release statement based on a filing with the Securities an... Full story
Yahoo Finance • 10 months ago
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairm... Full story
Yahoo Finance • last year
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) (Nasdaq: IRD), a clinical-stage gene t... Full story
Yahoo Finance • last year
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns
Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate Second Major Transaction in Six Months Undertaken Without Stockholder Input w... Full story
Yahoo Finance • last year
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete enrollment in Q2 202... Full story
Yahoo Finance • last year
Opus Genetics Announces Financial Results for Full Year 2024
Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance N... Full story
Yahoo Finance • last year
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics
Believes that Current Board’s Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction Highlights Serious Concerns with the Opus Merger and the Company’s Underperformance Preliminary Proxy Mate... Full story
